Clinical trials: Biomarker in Early Diagnosis
Breast Cancer
Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer
In the proposed project the investigators will asses whether changes in expression of selected circulating microRNAs in serum could comprise a sensitive and specific biomarker of cardiotoxicity in cancer patients treated with…
- Trial name
- NCT02065908
- Where
- 3 sites in Poland
- Volunteers
- 128 people
- Sponsor
- West Pomeranian Cancer Center
Acute Kidney Injury, Hepatorenal Syndrome
Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis
The purpose of this study is to test the accuracy of urinary neutrophil-gelatinase associated lipocalin (NGAL) and other biomarkers (plasma renin, norepinephrine) to predict acute kidney injury (AKI) development in patients with…
- Trial name
- NCT02049125
- Where
- 4 sites in Brazil
- Volunteers
- 300 people
- Sponsor
- University of Sao Paulo
Colorectal Cancer, Advanced Colorectal Neoplasm
A Stool DNA-based SDC2 Methylation Test for the Early Detection of Colorectal Cancer
The primary objective of this clinical trial is to determine the sensitivity and specificity of the EarlyTect® CRC test for detecting CRC, using colonoscopy as the reference method.
- Conditions
- Colorectal Cancer, Advanced Colorectal Neoplasm, Advanced Adenomas, Non-neoplastic Polyps
- Trial name
- NCT05255588
- Testing
- EarlyTect® CRC test
- Where
- South Korea
- Volunteers
- 2,358 people
- Sponsor
- Genomictree, Inc.
Liver Diseases
Early Detection of Hepatocellular Carcinoma in a High-risk Prospective Cohort (ELEGANCE)
Hepatocellular carcinoma (HCC) is the 7th most common cause of cancer death globally but only 20% are diagnosed in its early stages where cure is possible.
- Trial name
- NCT04965259
- Where
- 14 sites in Singapore
- Volunteers
- 2,002 people
- Sponsor
- National Cancer Centre, Singapore
Ulcerative Colitis (UC), Fecal Calprotetin
Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis
This multicenter prospective cohort aims to evaluate whether combined changes in fecal calprotectin (FC) and fecal immunochemical test (FIT) at Week 2 and Week 4 after initiating biologic therapy (vedolizumab or infliximab) can…
- Conditions
- Ulcerative Colitis (UC), Fecal Calprotetin, FIT
- Trial name
- FORESEE-UC (NCT07111572)
- Testing
- fecal calprotectin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Hospital of Shandong University
Breast Cancer
Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer
The GATHER trial aim to evaluate the diagnostic performance of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT in predicting pCR following neoadjuvant chemotherapy.
- Trial name
- GATHER (NCT07593976)
- Testing
- [68Ga]Ga-NOTA-anti-HER2-sdAb Positron Emission Tomography
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Centre Henri Becquerel
Lung Cancer
Exhaled Breath Biomarkers in Lung Cancer
Analysis of volatile organic compounds (VOCs) is a new attractive non-invasive field in medical diagnostics. These VOCs can be detected via the exhaled breath.
- Trial name
- NCT01386203
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Sheba Medical Center
Pancreatic Cancer, Pancreatic Neoplasms
Pancreatic Cancer Screening Using the Enzeavour Assay in Japan
This nationwide, multicenter, prospective, single-arm interventional feasibility study evaluates the Enzeavour Pancreatic Cancer assay in routine health checkups and cancer screening in Japan.
- Trial name
- ENZEAVOUR FS (NCT07605819)
- Testing
- Enzeavour Pancreatic Cancer Assay
- Where
- 69 sites in Japan
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Cosomil, Inc.
Coronary Bypass Graft Occlusion
Diagnostic and Prognostic Value of Cardiac Biomarkers for Early Coronary Bypass Occlusion in Patients Undergoing Coronary Revascularization
This study is to evaluate the correlation between hs-cTn level as cardiac biomarker for ischemia and early graft occlusion as assessed by CCT in patients undergoing coronary bypass surgery.
- Trial name
- NCT04595630
- Testing
- data collection from the hospital records
- Where
- 3 sites in Croatia, Poland and 1 more
- Volunteers
- 480 people
- Sponsor
- University Hospital, Basel, Switzerland
Early-Stage Breast Cancer, Neoadjuvant Therapy
COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer
The COGNITION diagnostic platform elucidates the biomarker profile of neoadjuvant chemotherapy-resistant residual bulk tumors in high risk early breast cancer patients.
- Trial name
- COGNITION (NCT05906407)
- Testing
- Genomic Profiling / Sequencing
- Where
- 12 sites in Germany
- Volunteers
- 2,000 people
- Sponsor
- German Cancer Research Center
Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
This study will look at the blood and cerebrospinal fluid of consented participants who either have early stage multiple sclerosis (clinically isolated syndrome) or who have later stage (secondary progressive multiple sclerosis)…
- Conditions
- Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Clinically Isolated Syndrome
- Trial name
- NCT01737372
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- John F. Foley, MD
Breast Cancer
A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy
To assess the effects of short term administration of celecoxib 400 mg bid between biopsy and reexcision.
- Trial name
- NCT00328432
- Testing
- celecoxib 400 mg bid
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Kansas
Type 1 Diabetes Mellitus With Diabetic Nephropathy
Validation of Biomarkers of Diabetic Nephropathy in Type I Diabetic Children
About 30 to 40% of patients suffering from type I diabetes are at risk of developing a diabetic nephropathy (DN) leading more or less rapidly to an end-stage renal disease.
- Trial name
- peeDIAB2 (NCT02164279)
- Testing
- Urinary sample collection
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Toulouse
Parkinson Disease, Progressive Supranuclear Palsy
Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes
Parkinson's disease (PD) is the most common degenerative Parkinson's syndrome and is linked, among other things, to the excessive accumulation of an abnormally aggregating protein, alpha-synuclein.
- Trial name
- SODIPARK (NCT06155942)
- Testing
- 7 Tesla MRI
- Where
- 6 sites in France
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Parkinson Disease, Amyotrophic Lateral Sclerosis (ALS)
Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders
Neurodegenerative disorders (NDDs), such as Parkinson¿s disease (PD), Alzheimer¿s disease (AD), Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) are characterized by aggregation and intracellular accumulation…
- Conditions
- Parkinson Disease, Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Alzheimer's Disease (AD)
- Trial name
- NCT06803784
- Testing
- Genetic: whole genome sequencing, whole exome sequencing
- Where
- Italy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Huntington Disease
Time-Restricted Eating in Huntington's Disease: A Clinical Pilot Study
This trial examines whether 12 weeks of time-restricted eating (TRE), otherwise known as intermittent fasting, appears safe and feasible in persons with early-stage Huntington's disease (HD).
- Trial name
- TREHD (NCT06490367)
- Testing
- Time-Restricted Eating Diet
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Oregon Health and Science University
Lung Cancer
Precision Diagnosis and Therapy for Early Stage Lung Cancer
The present study is a single arm clinical trial aiming to improve the key technology in the diagnosis and treatment of early stage lung cancer.
- Trial name
- NCT02936804
- Testing
- Low Dose Computed Tomography
- Where
- China
- Volunteers
- 60,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Chest Hospital
Parkinson Disease
Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease
The purpose of this study is to assess the efficacy, the safety, and the effect on biomarkers of 2 dose levels of oral GT-02287 over placebo after 48 weeks of treatment in treated and untreated participants with early PD.
- Trial name
- NCT07280299
- Testing
- Low Dose GT-02287, High Dose GT-02287
- Volunteers
- 111 people
- Sponsor
- Gain Therapeutics, Inc.
Breast Cancer, Depression
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
RATIONALE: Studying samples of blood in the laboratory from patients with breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to fatigue.
- Conditions
- Breast Cancer, Depression, Fatigue, Sleep Disorders
- Trial name
- NCT01286233
- Testing
- Metformin
- Where
- 256 sites in United States, Canada
- Volunteers
- 394 people
- Sponsor
- NSABP Foundation Inc
Major Depressive Disorder (MDD)
Predictors of Relapse in Major Depressive Disorder (PERFORM-D)
Major depressive disorder (MDD) is a common condition involving recurring periods of depression. One of the major challenges faced by people with MDD is that the episodes of depression tend to recur even after they are…
- Trial name
- PERFORM-D (NCT06746155)
- Where
- 9 sites in Canada
- Volunteers
- 252 people
- Sponsor
- Abraham Nunes